**AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis**

- 83 Percent of Patients Achieved EASI-50 at Day 29 Following a Single Dose of ANB020
- EASI-50 was Observed Early and Persisted Through Day 57
- Management to Host Conference Call Today at 8:30 a.m. EDT

SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class on unmet medical needs in inflammation, today announced positive proof-of-concept data for ANB020, its investigational anti-IL-33 therapeutic antibody in adult patients with moderate-to-severe atopic dermatitis. After a single dose of ANB020, 75 percent of patients achieved an Eczema Area Severity In percent relative to enrollment baseline (EASI-50) at day 15, 83 percent of patients achieved EASI-50 at day 29 and 75 percent of patients achieved EA achieved EASI-50 at one or more timepoints through Day 57 post-ANB020 administration. ANB020 was generally well tolerated in all patients as of this

"Moderate-to-severe atopic dermatitis is a serious disease associated with chronic skin inflammation and debilitating pruritus, with a clear unmet medica professor of dermatology at University of Oxford and primary investigator of the Phase 2a study. "The rapid and sustained benefit observed in patients a encouraging interim result from this trial. I look forward to the continued development of ANB020 as a potential future therapeutic option for patients suf

**Phase 2a Trial Design**

The Phase 2a proof-of-concept trial enrolled 12 moderate-to-severe adult atopic dermatitis patients, who were initially administered a single intravenous enrollment, followed by a single intravenous 300mg dose of ANB020 one week subsequent to placebo. Clinical response was assessed by the improve tool used to measure the extent and severity of atopic dermatitis, at key time points following ANB020 administration relative to their enrollment baselin as measured by the 5-D pruritus scale score, was also assessed for each patient. Exploratory mechanistic biomarkers included granulocyte infiltration lesions measured five days after placebo administration and five days after ANB020 administration.

**Interim Analysis**

An interim analysis conducted after all 12 patients had reached day 57 following ANB020 single administration, indicates the following:

- The average baseline EASI score upon enrollment was 32. The average EASI score reduction and pruritus score reduction at seven days post-place and 10 percent, respectively. All 12 patients were inadequately controlled by topical corticosteroids and seven were treated with systemic non-biolog the screening washout period of this trial.
- Rapid clinical response was observed at day 15 post-ANB020 administration with nine of 12 patients (75 percent) achieving EASI-50, of which three EASI score improvement of 75 percent relative to baseline (EASI-75). The average EASI score reduction at day 15 was 58 percent and the average relative to baseline.
- At day 29 post-ANB020 administration, 10 of 12 patients (83 percent) achieved EASI-50, of which four patients (33 percent) also achieved EASI-75. this time point was 61 percent and the average pruritus reduction was 32 percent relative to baseline.
- Sustained clinical response was observed at day 57 post-ANB020 administration, with nine of 12 patients (75 percent) achieving EASI-50, of which f achieved EASI-75. Average EASI reduction was 62 percent and the average pruritus reduction was 21 percent relative to baseline.
- Exploratory biomarker assessment indicated reduction of granulocyte infiltration into localized skin lesions by an average of 30 percent amongst all p patients achieving EASI-50 at 29 days post-ANB020 administration, while exploratory cytokine biomarker levels were below detection limit and there
- ANB020 was generally well-tolerated by all patients and no severe adverse events have been reported to date. The most frequent treatment-emerge dizziness in two patients subsequent to placebo dosing, and mild headache in two patients post-ANB020 administration.

"We are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-infla help patients suffering from debilitating inflammatory diseases," said Hamza Suria, president and chief executive officer of AnaptysBio. "We look forwar development of ANB020 for the treatment of patients with atopic diseases."

The Phase 2a study is currently ongoing and EASI scores will be assessed for each patient up to 140 days post-ANB020 treatment. The company plan medical conference following study completion.

During the first half of 2018, AnaptysBio plans to initiate a Phase 2b randomized, double-blinded, placebo-controlled study in 200-300 adult patients wit dermatitis to evaluate multi-dose subcutaneous administration of ANB020, with data expected in 2019.

AnaptysBio also continues to advance its ongoing ANB020 Phase 2a studies in adults with severe peanut allergy with topline data expected in the fourt severe eosinophilic asthma with topline data expected in the first half of 2018.

**Conference Call & Webcast Information**

The AnaptysBio management team will host a conference call and live webcast with slides with the investment community today, Tuesday, October 10, the information in this press release.

When: October 10, 2017, 8:30 a.m. EDT
Dial-in: (833) 696-8361 (domestic) or (430) 775-1625 (international)
Conference ID: 93436997

The live webcast and accompanying slides can be accessed under the investor relations section of AnaptysBio's website at www.anaptysbio.com. A re
archived under the investor relations section of the AnaptysBio website for 30 days shortly after the call.

**About ANB020**
ANB020 is an antibody that potently binds and inhibits the activity of interleukin-33, or IL-33, a pro-inflammatory cytokine that multiple studies have indi
diseases, including asthma, food allergies and atopic dermatitis. Following completion of a healthy volunteer Phase 1 trial of ANB020, AnaptysBio is cc
ANB020 into Phase 2a studies for moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma.

**About AnaptysBio**
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflamn
anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanu
asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar p
checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activate
an animal model of graft-versus-host disease. AnaptysBio's antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) p
antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery
developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including a
042), an anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), which are currently under clinical development w
checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene.

**Forward-Looking Statements**
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Ac
the anticipated timing of the release of data from AnaptysBio's clinical trials, including ANB020's Phase 2a clinical trials for the treatment of moderate-tc
severe peanut allergy and severe adult eosinophilic asthma and planned Phase 2b clinical trial of ANB020 for the treatment of moderate-to-severe adul
ability to launch a Phase 2b clinical trial of ANB020 for the treatment of moderate-to-severe adult atopic dermatitis and the anticipated timing thereof, th
future therapeutic option for patients with moderate-to-severe adult atopic dermatitis and AnaptysBio's ability to further advance the development of AN
with atopic diseases. Statements including words such as "plan," "continue," "expect," or "ongoing" and statements in the future tense are forward-looki
statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ materially from those expressed or ir
statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimat
candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, t
intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with
Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or
statements to reflect events or circumstances after the date hereof.

**Contacts**:
Monique Allaire
THRUST Investor Relations
617.895.9511
monique@thrustir.com

Chelcie Lister
THRUST Investor Relations
910.777.3049
chelcie@thrustir.com

AnaptysBio, Inc.